Viatris has been granted a patent for methods and pharmaceutical formulations to treat dry eye disease. The patent involves administering varenicline through a nasal spray to activate the trigeminal nerve in individuals suffering from the condition. GlobalData’s report on Viatris gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Viatris, Cancer treatment biomarkers was a key innovation area identified from patents. Viatris's grant share as of February 2024 was 58%. Grant share is based on the ratio of number of grants to total number of patents.
Nasal spray method for treating dry eye disease
A recently granted patent (Publication Number: US11911380B2) discloses a method for activating the trigeminal nerve, anterior ethmoidal nerve, and nasolacrimal reflex in individuals by administering varenicline through local nasal cavity spray. The method involves using a liquid pharmaceutical formulation containing varenicline or its salt, along with inactive ingredients, at concentrations ranging from 0.1 mg/mL to 10 mg/mL. The administered varenicline amount falls between 5 micrograms and 1000 micrograms, selectively binding to peripheral nicotinic acetylcholine receptors without causing significant psychoactive side effects or vomiting. The pharmaceutical formulation includes a phosphate buffer or phosphate citrate buffer with a pH between 5.0 and 7.4, ensuring effective and safe activation of the nerves.
Furthermore, the patent details the specific dosage ranges and administration techniques for varenicline to target the trigeminal nerve, anterior ethmoidal nerve, and nasolacrimal reflex successfully. By administering varenicline within the specified ranges (5-1000 micrograms) into the nasal cavity, the method aims to activate these nerves without inducing undesirable side effects. The inclusion of a suitable buffer system within the pharmaceutical formulation further enhances the efficacy and tolerability of the administered varenicline. Overall, the patent provides a novel approach to nerve activation through local nasal administration of varenicline, offering a potential therapeutic strategy for individuals in need of trigeminal nerve, anterior ethmoidal nerve, and nasolacrimal reflex activation.
To know more about GlobalData’s detailed insights on Viatris, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
